Joshua Schimmer Recent News
Bluebuird Bio Crashes Nearly 30%: What's Next?
5 Biotechs That Can Win From Ophthalmology Innovation
Calls Of Note: The Research Moving Stocks Today
Piper Jaffray On Biogen Downgrade: '6 MG Data Does Not Inspire Confidence…Even More Speculative Than Before'
Piper Jaffray Dishes On MannKind's Afrezza Data
Biogen Or Bluebird: Which Will Lead In SCD?
Piper Jaffray Names Chimerix Inc Top Ebola Play
Piper Jaffray Not Convinced MannKind's Afreeza Will Be Commercial Success
Shares of MannKind Plummet Prior to Drug Advisory Meeting
Piper Sees "Meaningful Utility" from GW Phamaceuticals CBD, Reiterates Overweight Rating
UPDATE: Piper Jaffray Initiates On Amgen On Series Of Bold Steps
UPDATE: Piper Jaffray Initiates on Alexion on High Revenue and EPS Growth Rates
UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On BMN-111 Outlook
UPDATE: Piper Jaffray Maintains Overweight On Vanda Pharmaceuticals On Hetlioz Outlook
Lazard Capital Markets Reiterates Buy on Vanda Pharmaceuticals on Good Entry Point
Leerink Swann Reiterates Incyte (INCY) Outperform Rating
Leerink Swann Reiterates Gilead Science (GILD) Outperform Rating